This inventor holds 5 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Array Biopharma Inc., Genentech, Inc., Intermune, Inc.. Active years: 2007-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 333 
3 out of 3,300 
1 out of 52 
Years Active: 2007-2015
Title: **Innovative Contributions of Steven Mark Wenglowsky in Biotechnology**
Introduction
Steven Mark Wenglowsky is a notable inventor based in Boulder, Colorado, recognized for his significant contributions to the field of biotechnology. With a portfolio of five patents, he has been instrumental in developing cutting-edge therapies aimed at treating various hyperproliferative disorders. His work reflects a deep commitment to advancing medical science through innovative solutions.
Latest Patents
Wenglowsky's latest patents showcase his expertise in developing highly specialized compounds. His patent on **Serine/threonine kinase inhibitors** discloses compounds with the formula I, which serve as inhibitors of ERK kinase. This breakthrough includes compositions and methods for treating hyperproliferative disorders, marking a significant advancement in targeted therapies. Additionally, he holds a patent for **Pyrazole [3, 4-B] pyridine Raf inhibitors**, which are compounds of Formula I that are effective in inhibiting Raf kinases. This patent outlines methods for using these compounds—along with their stereoisomers, tautomers, prodrugs, and pharmaceutically acceptable salts—for the diagnosis, prevention, or treatment of related disorders in mammalian cells.
Career Highlights
Throughout his career, Wenglowsky has worked with prominent companies in the biotechnology field. Notably, he was associated with **Array Biopharma Inc.** and **Genentech, Inc.**, where he contributed to groundbreaking research and development initiatives. His experience in these organizations has significantly shaped his innovative approaches and contributions to the industry.
Collaborations
Steven has collaborated with talented professionals like Li Ren and Kateri Ahrendt, enhancing the impact of his research through teamwork. These collaborations have fostered a productive environment for idea exchange and innovation, further pushing the boundaries of biomedical science.
Conclusion
In summary, Steven Mark Wenglowsky stands out as a pivotal figure in biotechnology, with a proven track record of patenting valuable innovations. His latest work on kinase inhibitors demonstrates his dedication to addressing complex medical challenges. As technology continues to evolve, his contributions will undoubtedly play a crucial role in shaping future advancements in therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile